Matthew Korenberg - Ligand Pharmaceuticals CFO and VP of Fin.
| LGND Stock | USD 121.47 1.08 0.88% |
CFO
Mr. Matthew E. Korenberg is Chief Financial Officer, Executive Vice President Finance of the Company. He has served as our Executive Vice President, Finance and Chief Financial Officer since January 2018 and prior to that as our Vice President, Finance and Chief Financial Officer since August 2015. Prior to joining Ligand, commencing in September 2013, Mr. Korenberg was the founder, Chief Executive Officer and a director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial focus on Down syndrome. Prior to founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at Goldman Sachs from July 1999 through August 2013. During his 14 year tenure at Goldman Sachs, Mr. Korenberg was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and San Francisco. Prior to Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read Co. Inc. where he spent two years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies since 2018.
| Age | 49 |
| Tenure | 6 years |
| Address | 555 Heritage Drive, Jupiter, FL, United States, 33458 |
| Phone | 858 550 7500 |
| Web | https://www.ligand.com |
Matthew Korenberg Latest Insider Activity
Tracking and analyzing the buying and selling activities of Matthew Korenberg against Ligand Pharmaceuticals stock is an integral part of due diligence when investing in Ligand Pharmaceuticals. Matthew Korenberg insider activity provides valuable insight into whether Ligand Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Ligand Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ligand Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Matthew Korenberg over three months ago Disposition of 5212 shares by Matthew Korenberg of Ligand Pharmaceuticals at 106.3214 subject to Rule 16b-3 | ||
Matthew Korenberg over three months ago Disposition of 4275 shares by Matthew Korenberg of Ligand Pharmaceuticals at 105.1319 subject to Rule 16b-3 | ||
Matthew Korenberg over three months ago Disposition of 1157 shares by Matthew Korenberg of Ligand Pharmaceuticals at 105.54 subject to Rule 16b-3 |
Ligand Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.013 % which means that it generated a profit of $0.013 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.06 %, meaning that it created $0.06 on every $100 dollars invested by stockholders. Ligand Pharmaceuticals' management efficiency ratios could be used to measure how well Ligand Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ligand Pharmaceuticals' Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.07, whereas Return On Equity is forecasted to decline to 0.07. At present, Ligand Pharmaceuticals' Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 385.2 M, whereas Other Current Assets are forecasted to decline to about 3.6 M.Similar Executives
| Found 4 records | CFO Age | ||
| Robert Goeltz | Arcus Biosciences | 47 | |
| Sung Lee | Cytokinetics | 54 | |
| Timothy Sullivan | Apellis Pharmaceuticals | 53 | |
| Aaron Rosenberg | BeiGene | 48 | |
Management Performance
| Return On Equity | 0.06 | ||||
| Return On Asset | 0.013 |
Ligand Pharmaceuticals Leadership Team
Elected by the shareholders, the Ligand Pharmaceuticals' board of directors comprises two types of representatives: Ligand Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ligand. The board's role is to monitor Ligand Pharmaceuticals' management team and ensure that shareholders' interests are well served. Ligand Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ligand Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vincent Antle, Senior Capitsol | ||
| Paul Hadden, Senior Development | ||
| Michael Jeong, Head Relations | ||
| Audrey WarfieldGraham, Chief Officer | ||
| Karen MD, Senior Strategy | ||
| Richard Baxter, Senior Operation | ||
| Todd Pettingill, Sr. Manager - Corporate Development and Investor Relations | ||
| Todd Davis, Independent Director | ||
| Todd CFA, Director Development | ||
| Andrew JD, Chief Secretary | ||
| Patrick Lucy, Senior Business | ||
| Matthew Korenberg, CFO and VP of Fin. | ||
| John Higgins, CEO and Executive Director | ||
| Simon Latimer, Head Relations | ||
| Octavio Espinoza, Chief Officer | ||
| Scott Plesha, CEO Therapeutics | ||
| Keith Marschke, Senior Affairs |
Ligand Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ligand Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.06 | ||||
| Return On Asset | 0.013 | ||||
| Profit Margin | 0.30 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 2.1 B | ||||
| Shares Outstanding | 18.9 M | ||||
| Shares Owned By Insiders | 1.88 % | ||||
| Shares Owned By Institutions | 98.12 % | ||||
| Number Of Shares Shorted | 831.45 K | ||||
| Price To Earning | 29.74 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ligand Pharmaceuticals is a strong investment it is important to analyze Ligand Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ligand Pharmaceuticals' future performance. For an informed investment choice regarding Ligand Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.032 | Earnings Share 2.49 | Revenue Per Share 8.509 | Quarterly Revenue Growth 0.576 | Return On Assets 0.013 |
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.